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Cognitive and motor disturbances are serious consequences of tremor induced by motor 
disorders. Despite a lack of effective clinical treatment, some potential therapeutic agents have 
been used to alleviate the cognitive symptoms in the animal models of tremor. In the current 
study, the effects of WIN55, 212-2 (WIN), a cannabinoid receptor (CBR) agonist, on harmaline-
induced motor and cognitive impairments was studied. Adult rats were treated with WIN (0.5 
mg/kg; i.p.) 15 min before harmaline administration (10 mg/kg; ip) after which exploratory and 
anxiety related behaviors, and cognitive function were assessed using open-field behavior and 
shuttle box tests. Rats that received harmaline only exhibited a markedly reduced number of 
central square entries when compared to harmaline vehicle-treated controls, whereas those 
treated with WIN and harmaline showed a significant increase in central square entries, 
compared to harmaline only treated. The passive avoidance memory impairments observed in 
harmaline treated rats, was reversed somewhat by administration of WIN. The neuroprotective 
and anxiolytic effects of WIN demonstrated in the current study can be offered cannabinoid 
receptor (CBR) agonism as a potential neuroprotective agent in the treatment of patients with 
tremor that manifest mental dysfunctions. 
Keywords: WIN55, 212-2, Harmaline, CB agonism, Tremor, memory  
Abbreviations: WIN: WIN 55,212-2, CBR: cannabinoid receptor, ET: essential tremor, ACPA: 







Essential tremor (ET) is conventionally conceived of as a purely motor disease and some 
studies have revealed an association between ET and increased risk for cognitive impairment and 
dementia, which suggests that cognitive impairments in ET patients may be a consequence of an 
additional neurodegenerative disorder. However, other studies have identified cognitive deficits 
in ET patients as being frontosubcortical or corticocerebellar which are consistent with 
symptoms arising in whole or in part from ET itself and independent of medication used to treat 
ET symptoms (Janicki et al. , 2013). Furthermore, no pharmacotherapies to treat cognitive 
deficits in ET patients have been developed, revealing an unmet clinical need in this population. 
Predictive animal models of symptoms and disease remain an important element of drug 
development. Systemic harmaline administration causes action tremor in mammals and has 
proved to be a useful animal model for the discovery of new therapies for primary symptoms of 
ET (Clifford, 1983a). Furthermore, in addition to harmaline causing agitation, cytotoxicity, 
delirium, paralysis, loss of coordination, tremor, visual disturbances and hallucinations (Khan et 
al. , 2013), it has also been reported to induce cognitive disturbances, most likely as sequelae to 
low harmaline doses (5-10 mg/kg) acting anxiogenically or higher doses (20 mg/kg) exerting 
reportedly anxiolytic effects in rodents (Hilber and Chapillon, 2005). It has also reportedly 
affected emotional reactivity in mice as decision making in an anxiogenic situation can be altered 
by harmaline treatment (Hilber and Chapillon, 2005) in addition to inducing cognitive 
disturbances that manifest as motor and spatial learning impairments (Hilber and Chapillon, 
2005). Therefore, the symptoms exhibited by rodents following systemic harmaline 
administration are consistent with being predictive for drug effects upon cognitive domains of 
interest to human ET pharmacotherapy.  
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The endocannabinoid system is implicated in cognition and genetic deletion of 
cannabinoid type 1 (CB1) receptors  accelerates age-related cognitive decline in rodents 
(Jenniches et al. , 2015), accompanied by neuronal loss in the CA1 and CA3 regions of the 
hippocampus (Bilkei-Gorzo et al. , 2005). CB1 receptors are presynaptically located where 
activation reduces presynaptic neuronal excitability and so inhibits neurotransmitter release 
(Howard et al. , 2013). CB1 receptor expression is abundant in several brain regions including the 
hippocampus, prefrontal cortex, nucleus accumbens and amygdala where their modulation of 
neurotransmitter release exerts a variety of behavioral and cognitive effects (Khan, Maalik, 
2013). Here, a substantial body of evidence from animal models and human studies has shown 
that CB1 receptor agonists, frequently in the form of ∆
9
-tetrahydrocannabinol which is the 
principal psychoactive component derived from Cannabis sativa, induce numerous and complex 
effects on cognitive functions including attention, learning, emotional reactivity, enhancement of 
the perceptions of the senses, and, idiosyncratically, impairment and improvement in short-term 
memory (Barzegar et al. , 2015, Razavinasab et al. , 2013, Shabani et al. , 2009, Shabani et al. , 
2011). In the passive avoidance task, CB1 receptor activation reversed opioid-induced memory 
impairment (Zarrindast, 2006) but in other reports have been shown to impair passive avoidance 
learning in addition to adversely affecting spatial and working memory (Hasanein and Teimuri 
Far, 2015, Shabani et al. , 2012). For example, the CB1 receptor agonist, 
arachidonylcyclopropylamide (ACPA) induced memory acquisition impairment in mice which 
was reversed by co-administration of a CB1 receptor antagonist (Nasehi et al. , 2015a). 
Interestingly, prenatal administration of the CB receptor agonist, WIN55,212-2 (0.5-1mg/kg) 
during embryonic days 5-20 can disrupt memory retention in offspring when assessed at P30-
P35 using the passive avoidance task (Shabani, Divsalar, 2012). A role for CB1 receptors in 
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memory consolidation was shown by treatment with the CB1 receptor selective antagonist, 
rimonabant (0.1 mg/kg and 1.0 mg/kg; i.p.), which caused significant improvement in passive 
avoidance performance (Ágota S. Ádáma et al. , 2008). Moreover, alterations in the sleep–wake 
cycle, memory formation, locomotor activity and pain perception have been widely reported in 
studies of the effects of the endocannabinoid, anandamide (Arjmand et al. , 2015,             -
                 . , 1998). 
In the present study, we examine the effect of harmaline at a reportedly low, anxiogenic 
dose (10 mg/kg; i.p.) upon tremor, gait, anxiety and associative learning and memory in rats 
before investigating the effects of cannabinoid receptor agonism upon harmaline-induced effects 
in these domains. Here, harmaline produced a moderate and persistent tremor, gait disturbances, 
increased anxiety and a significant impairment in the learning and recall capability in the passive 
avoidance task. While prior CBR agonist treatment had no effect upon harmaline-induced tremor 
or gait disturbances, the anxiogenic effects of harmaline were attenuated and some impairments 
of memory formation and retention were reversed.    
2. Methods and materials 
2.1 Animals 
30 adult, male Wistar Kyoto rats (60-80 g) were used. Animals were kept in individual cages 
with access to food and water ad libitum and maintained on a 12 hours/12 hours dark/light cycle. 
Every effort was made to minimize animal suffering during all stages on the study. All 






The non-selective cannabinoid type 1 (CB1) and type 2 (CB2) receptor agonist, WIN55, 212-2 
(WIN; Sigma, USA), was dissolved in dimethylsulfoxide (DMSO) before 100-fold dilution in 
normal saline. Harmaline hydrochloride dihydrate (Sigma) was dissolved in normal saline. 
 
2.3. Behavioural tasks 
2.3.1. Tremor scoring 
Tremor was rated by two observers blinded to treatment. Intra- and inter-observer reliability 
were assessed via kappa coefficient (acceptance criterion: >80%). Tremor data were acquired 
during the open field test and quantitatively scored as follows: 0: No tremor, 1: occasional tremor 
affecting only the head and neck, 2: intermittent (occasional tremor affecting all body parts), 3: 
persistent (persistent tremor affecting all body parts and tail), 4: severe (persistent tremor 
rendering the animal unable to stand and/or walk) (Al-Deeb S1, 2002 )  
 
2.3.2. Gait analysis 
The footprint test assesses animal walking patterns and gait kinematics. The hind paws of each 
animal were marked with a non-toxic ink and the animal allowed to traverse a clear Plexiglas 
tunnel (100 cm [L]×10 cm [H]×10 cm [W]) lined with white absorbent paper (100 cm × 10 cm) 
and ending in a darkened cage. The resulting tracks provide the spatial relationship of 
consecutive footfalls from which animal stride length and width were measured. Animals were 
habituated to the runway for 3 training runs before testing. Hind paw stride lengths were 
measured by distance (cm) between the respective paw prints to the successive ipsilateral prints 
to assess uni- or bi-lateral effects of treatment upon gait. Hind paw stride widths were measured 
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by distance between the centers of the respective paw prints to the corresponding contralateral 
stride length measurements at a right angle. Footprints at the beginning and end of each run were 
not considered in the analysis(Wecker L, 2013;). 
 
2.3.3 Open-field test 
The open field apparatus consisted of a square Plexiglas arena (90 [W] ×90 [L] ×45 [H] cm), the 
floor of which was divided by lines into 16 squares to define central and peripheral regions. Each 
animal in turn was placed in the middle of the open field apparatus and vertical (rearing) and 
horizontal activity video recorded for a five-minute period. Video recordings were analyzed 
offline using EthoVision (Noldus Information Technology, Netherlands) video tracking software 
for automated classification of behavioral paradigms and the following parameters recorded for 
each animal: total distance moved (cm) and time spent in peripheral and central regions 
(seconds). At the end of each test, the animal was removed from the chamber and the field 
cleaned with 70% ethanol (Nazeri et al. , 2014). 
 
2.3.4. Passive avoidance test  
The passive avoidance task is a fear-aggravated test used to evaluate associative learning and 
memory in rodents. The animal learns to avoid an environment in which a prior aversive 
stimulus has been delivered. Here, passive avoidance learning was assessed using an inhibitory 
passive avoidance paradigm as described hereafter. Briefly, a shuttle-box device with dimensions 
of 100 [L] x 25 [W] x 25 [H] (cm) and consisting of two compartments (light and dark) separated 
by a door was used. In the learning phase of the test, each animal was first habituated to the test 
9 
 
equipment by placement in the light chamber (door closed) for 5 minutes before return to the 
home cage. The next day, the animal was returned to the light compartment, the door opened and 
the animal allowed to move to the dark chamber before the door was closed and the animal 
returned to the home cage. This process was repeated once and if an animal failed to move into 
the dark compartment, it was removed from the study. Finally, one hour after the previous 
exposure to the apparatus, the animal was placed into the light compartment, the door opened 
and, on entering the dark compartment, given an electric shock (0.5A, 2ms; via wires embedded 
in the dark chamber floor). This final part of the process was repeated up to five times at 1 hour 
intervals until the animal learned to avoid the dark compartment (remains in light compartment 
for at least 300s) and the number of shocks required for learning recorded. The assessment phase 
of the test was undertaken 24 hours after the learning phase. The animal was placed in the light 
chamber (door closed) and, after 30s, the door opened and the time until the animal entered the 
dark chamber recorded as the step-through latency (STL). The total time spent in the dark 
compartment (TDC) during a period of 5 minutes after door opening was also recorded. 
 
2.2. Experimental design 
Animals were divided into three groups (n=10/group). The control group (harmaline vehicle plus 
WIN vehicle) received WIN vehicle (normal saline; 0.5 ml; i.p.), 15 minutes before harmaline 
vehicle (normal saline; 0.5 ml; i.p.). The harmaline only group (WIN vehicle plus harmaline) 
received WIN vehicle (normal saline; 0.5 ml; i.p.), 15 minutes before harmaline (10 mg/kg; i.p.). 
The harmaline plus WIN group (WIN plus harmaline) received WIN (0.5 mg/kg; i.p.), 15 
minutes before harmaline injection (10 mg/kg; i.p.). Each group began behavioural testing as 
described hereafter 30 minutes after receiving harmaline vehicle (control) or harmaline 
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(harmaline only and harmaline plus WIN groups). Each group undertook four behavioral tests: 
open field test, tremor score evaluation and gait analysis which were administered sequentially 
with 15 minute rest interval between each test. The learning phase of the passive avoidance task 
was undertaken 3 hours after gait analysis when tremor symptoms had subsided, while 
assessment of memory retrieval in the task was performed 24 hours after the learning phase. 
 
2.3. Statistical analysis  
SPSS (IBM, USA) and GraphPad Prism 6 (GraphPad Software, USA) were used for 
statistical analysis of data and figure production. All data were first assessed for normality using 
a Kolmogorov-Smirnov test. Results found to be normally distributed (p>0.05 in K-S test) were 
expressed as mean±SEM and analyzed using a one-way ANOVA test. Where a main effect was 
s  n  n ANOVA   s s, p   w s    mp   s ns b  w  n     ps w     h n m     s n  T k y’s 
post-hoc tests. Results that were not normally distributed (p<0.05 in K-S test) were expressed as 
median and interquartile range (expressed as median (interquartile range)) and analysed using a 
Kruskal-Wallis test. Where a main effect was seen in Kruskal-Wallis tests, pairwise comparisons 
between groups were then made using Dunn's multiple comparisons test. In each case, p<0.05 
was considered statistically significant.  
3. Results 
3.1 Effect of harmaline and CBR agonism on motor behaviours 
When tremor was examined, a main effect of treatment was observed (H(2)=24.4; p<0.001; 
Fig.1A). Subsequent post hoc tests revealed that both the harmaline (p<0.001) and harmaline 
plus WIN (p<0.01) groups exhibited significantly greater tremor scores when compared to 
control animals although no significant difference was seen between harmaline and harmaline 
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plus WIN55,212-2 groups, suggesting that WIN55,212-2 treatment had no effect upon harmaline 
induced tremor. 
 In the gait analysis test, a main effect of treatment upon step width was detected (F2, 
27=8.1; p<0.001; Fig.1B). Post hoc pairwise comparisons revelaed that both harmaline only and 
harmaline plus WIN groups exhited significantly increased step width (both P<0.001 vs control) 
although a significant difference between harmaline only and harmaline plus WIN groups was 
also detected (P<0.05) demonstrating that WIN treatment was able to partly ameliorate 
harmaline effects upon this parameter. Moreover, a main effect of treatment upon left and right 
step lengths was also detected (H(2)=16.11; p=0.0003 and F2,30=83.8; p<0.0001 respectively; 
Figs 1C&D). Post hoc paiwise comparisons revealed that left and right stride lengths were 
significantly decreased by both harmaline only (left & right: p<0.001) and harmaline plus WIN 
treatments (left: p<0.01; right: P<0.001) to reveal that WIN treatment has no effect upon 
harmaline-induced disturbances in stride length. 
 
3.2 CBR agonism ameliorates harmaline-induced anxiety-like, but not exploratory 
behaviours  
In the open field test, an overall effect of treatment upon total distance moved (F2, 23=112.7; 
p<0.0001; Fig.2A), velocity (F2, 27=149.2; p<0.0001; Fig.2B), time spent in the center (F2, 
24=52.3; p<0.0001; Fig.2C) and time spent in the perimeter (F2, 24=51.4; p<0.0001; Fig.2D) was 
found. Post hoc pairwise comparisons revealed that harmaline only and harmaline plus WIN 
significantly reduced total distance moved (harmaline only & harmaline plus WIN: p<0.001 vs 
control) and velocity (harmaline only & harmaline plus WIN: p<0.001 vs control). Therefore, it 
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is clear that WIN treatment has no effect upon harmaline-induced changes in distance moved or 
velocity. 
 However, when post hoc pairwise comparisons were conducted between groups for 
measures of time spent in the center and perimeter of the apparatus, a different pattern of effects 
emerged. Here, time spent in the center was significantly decreased in the harmaline only group 
(p<0.001 vs control) but not the harmaline plus WIN group (p>0.5 vs control). Moreover, the 
harmaline-only group was signifciantly decreased compared to the harmaline plus WIN group 
(p<0.001) demonstrating that WIN treatment was able to reverse the harmaline-induced effects 
on this measure observed. Correspondingly, time spent in the perimeter was significantly 
increased in the harmaline only group (p<0.05 vs control) and decreased in the harmaline plus 
WIN group (p<0.001 vs control). Moreover, the harmaline-only group was signifciantly 
increased compared to the harmaline plus WIN group (p<0.001), again demonstrating a WIN-
induced reversal of harmaline effects. 
 
3.3 Harmaline-induced impairment of performance in the passive avoidance test can be 
partially reversed by CBR agonism 
In the passive avoidance test, an overall effect of treatment was seen upon the number of shocks 
required before learning was achieved (H(2)=14.98; p<0.001; Fig. 3A) where subsequent 
pairwise comparisons revealed that while harmaline only treated animals required significantly 
more shocks (p<0.001 vs control), harmaline plus WIN treated animals did not differ from 
controls in their capacity to learn (p>0.5 vs control). In the assessment phase of the test which 
was undertaken 24 hours after learning, an overall effect of treatment upon step through latency 
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was found (F2, 27=35.93; p<0.0001; Fig.3B) where post hoc pairwise comparisons revealed that 
this measure was signifciantly decreased in both harmaline only and harmaline plus WIN groups 
(both p<0.001 vs control) although the harmaline plus WIN group was signifciantly increased 
when compared with the harmaline only group (p<0.01) indicating that WIN treatment was able 
to partially ablate the harmaline-induced reduction in step through latency. Finally, when time 
spent in the dark compartment during the assessment phase was examined, an overall effect of 
treatment was detected (F2, 24=21.09; p<0.0001; Fig.3C) and could be attributed to signifciantly 
increased values for this parameter exhibited by both the harmaline only and harmaline plus 
WIN groups (both p<0.001 vs control). 
 
3. Discussion 
Affective and cognitive symptoms represent an emerging symptom domain in ET and for 
effective therapeutic interventions to be developed, require the development of, and examination 
in, appropriate animal models of symptoms and disease. Here, we evaluated the effect of a 
moderate, systemic dose harmaline, previously reported to produce some tremor and anxiogenic 
symptoms in mice, upon rats. Thereafter, we examined the effect of CB receptor agonist 
pretreatment upon harmaline-induced symptoms. Since CB receptor agonism has not only been 
reported to exert complex and dose dependent effects upon measures of cognition, but has also 
been anecdotally used to manage motor symptoms and affective disorders (Ware et al. , 2005). 
Harmaline reliably induced moderate tremor consistent with previous behavioural studies 
which have shown similar effects such as ataxia, motor deficits and catatonia (Nasehi et al. , 
2010, Vaziri et al. , 2015). Moreover, gait analysis revealed increased step width with 
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simultaneously decreased step length bilaterally. CB receptor agonist pretreatment did not affect 
harmaline-induced tremor or gait defects which is notable since CB receptor activation by the 
psychoactive plant cannabinoid, Δ9-THC, typically produces motor disturbances in rodents 
(Taylor and Fennessy, 1982), dogs and humans yet has also been anecdotally claimed to exert 
beneficial effects in tremor disorders (Clifford, 1983b, Fitzgerald et al. , 2013). It is possible that 
the moderate tremor induced by 10mg/kg harmaline may not have been of a sufficient magnitude 
for any beneficial or detrimental effect of CB receptor agonism thereupon to be detected (i.e. 
inadequate effect size). 
In the open field test, harmaline decreased both velocity and the total distance moved 
suggesting that treatment may be anxiogenic although harmaline-induced motor dysfunction 
(tremor and gait) may have directly impaired locomotor activity, independent of any effect upon 
anxiety. However, when the time spent in the different areas of the apparatus was assessed, 
harmaline treatment caused a decrease in time spent in the center and a corresponding increase in 
time spent in the perimeter suggesting that, irrespective of direct effects of harmaline upon motor 
function, treatment was anxiogenic, consistent with previously reported evidence in mice in the 
elevated plus maze (Hilber and Chapillon, 2005). Interestingly, while CB receptor agonism had 
no effect upon harmaline-induced deficits in velocity and distance moved, it did reverse 
h  m   n ’s  nx    n    ff   s  s  ss ss   by   m  sp n   n  h    ff   n      s  f  h   p n f     
apparatus.  Therefore, our results indicate an important role of the endocannabinoid system in the 
modulation of stress-responses and these findings are consistent with the knowledge that an 
interrupted endocannabinoid signaling contributes to the progress of affective disorders, which is 
supported by clinical data like investigating the characteristics and patterns of cannabis and other 
drug use among long-term cannabis users in an Australian rural area, showed the most common 
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reasons for using cannabis were for relaxation or relief of tension and enjoyment or to feel good. 
The most commonly reported negative effects were feelings of anxiety, paranoia, or depression, 
tiredness, lack of motivation and low energy (Reilly et al. , 1998) and to examine the reasons for 
cannabis use among individuals with psychotic disorders, found that boredom, social motives, 
improving sleep, anxiety and agitation and symptoms associated with negative psychotic 
symptoms or depression were the most important motivators of cannabis use (Schofield et al. , 
2006). 
There is the hypothesis of fundamental and long-term changes in behavioral patterns due 
to cannabis consumption (Kowal et al. , 2011a, Shabani, Divsalar, 2012). They argue that such 
changes caused by the effects of cannabis on neurotransmitter systems, including opioidergic, 
GABAergic, glutamatergic dopaminergic and serotonergic systems, for example in the study of 
Mikael A. Kowal (Kowal et al. , 2011b), the results point to less efficient striatal dopaminergic 
functioning in chronic cannabis users. This finding seems crucial in understanding the suspected 
psychotic effects of long-term cannabis use and throws some doubts on the claim that cannabis-
induced psychosis results from the combination of increased striatal and reduced prefrontal DA 
levels.  
In the passive avoidance test, harmaline treatment impaired learned inhibition as 
indicated by the increased number of shocks required before animals met criterion and this 
impairment was not affected by CB receptor activation by WIN55, 212-2. When memory was 
assessed in the passive avoidance test, harmaline treatment impaired acquisition of passive 
avoidance as demonstrated by a shorter step through latency and longer time spent in the dark 
compartment. However, unlike learned inhibition, CB receptor agonism modulated this 
harmaline-induced impairment since WIN55,212-2 treatment partially reversed the harmaline-
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induced reduction in step through latency although the harmaline-induced increase in time spent 
in the dark compartment was unaffected. Animal studies have demonstrated that an acute 
administration of CB1    n s s ( . ., n          n s , Δ9-THC, and synthetic agonists, CP55940 
and HU-210) and also pretraining administration of CB1/CB2 mixed agonist, WIN 55,212-2, 
attenuated acquisition of memory in various animal models (Abush and Akirav, 2010). In the 
water maze, systemic or local CA1 injections of AM251, WIN55, 212-2, and AM404 all 
impaired spatial learning, suggestion that targeting the endocannabinoid system may aid in the 
treatment of disorders associated with impaired extinction-like processes, such as post-traumatic 
stress disorder (Kruk-Slomka et al. , 2015). There are several evidences that harmaline has a 
number of diverse effects such as excitation, euphoria, motor tremor, alteration in associative and 
motor learning and calcium channel opening, with a resultant rise in neuronal excitability 
(Nasehi, 2015). It has reported increased caspase-3 activation in the lack of the CB1 receptors in 
knockout mice, indicating the neuroprotective potential of these receptors (Jackson et al. , 2005). 
Harmaline neurotoxicity could be mediated by glutamate excitotoxicity which could result in 
neuronal cell death. However, CB1 receptor activation in the brain inhibited the presynaptic 
release of glutamate, which has been shown to prevent excitotoxicity, leading to cell death (Shen 
et al. , 1996). Cannabinoids have been shown to inhibit voltage-activated Ca
2+
 channels (Daniel 
and Crepel, 2001) and cause a hypoglutamatergic condition by inhibiting the release of glutamate 
(Chemin et al. , 2001).  
Previous behavioral studies such as step-down passive avoidance test, spontaneous eye 
blink rates, object recognition task,  have shown a number of different effects for harmaline, such 
as alteration in associative memory and learning with a resultant increase in neuronal excitability 
(Dahhaoui et al. , 1992, Moura et al. , 2006, Nasehi et al. , 2015b, Nasehi, Piri, 2010). Harmaline 
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had previously been demonstrated to adversely affect memory retrieval, consistent with our 
findings here (Dahhaoui, Stelz, 1992). However, other studies have reported that harmaline 
treatment can enhance long term memory in adult Swiss mice received an intra-peritoneal 
injection of beta-carbolines alkaloids, harmine and harmol (1.0, 2.5 or 5.0 mg/kg) 30 min before 
training in an object recognition task. They induced an enhancement of short-term memory 
(STM) at all doses tested when compared to controls. (Moura, Rorig, 2006). These apparently 
contradictory results may be explained by harmaline effects acting through a number of brain 
areas when administered systemically. Harmaline has been revealed to a lower voltage-gated 
calcium channel currents, resulting in decreased neuron excitation (Handforth et al. , 2010). 
Calcium influx stimulates cellular signaling pathways involved in memory processes. Nasehi et 
al (2015) suggested harmaline through reduction of neuron excitation could decrease memory 
acquisition (Nasehi et al. , 2015c).  
It was previously demonstrated that spatial learning and memory and passive avoidance 
learning and memory were negatively interfered with harmaline (Dahhaoui, Stelz, 1992). Our 
data did show administration of harmaline leads to impairments in memory retrieval of rats in 
contextual fear memory paradigms. The facilitative effect of WIN on memory extinction does 
not seem to be specific to contextual fear memory because it was also observed in the water 
maze reversal task (Hasanein and Teimuri Far, 2015). 
         In conclusion, the present study confirms that a moderate, systemic harmaline dose, in 
addition to inducing a classical tremor and motor disturbance, also elicits an anxiogenic response 
and impairs learned inhibition and acquisition of learned avoidance. Moreover, while systemic 
CB     n sm     n    ff    h  m   n ’s m      ff   s  n  h s m    ,  nx    nic and cognitive 
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7. Figure Legend:  
Figure 1: Effects of CBR agonist WIN on (A) tremor score, (B) step with, (C) left and (D) right 
step length after harmaline administration. (n=10 animals per group). Values show as 
means+SEM significantly different between harmaline versus control (** p<0.01 and 
***p<0.001) and WIN versus harmaline (# p<0.05) group. 
Figure 2: The effect of WIN55, 212-2 on explorative and anxiety like behavior changes induced 
by harmaline. Total distance moved (A) and velocity (B) decreased in harmaline and WIN 
groups. Anxiety like behaviors (C: time spent in the center; D: time spent in perimeter) altered 




p<0.001 as compared to the control group; 
### 
p<0.001 as compared to the harmaline group. 
Figure 3: The effect of harmaline - induced tremor and pretreatment with WIN on the fear 
learning in passive avoidance learning paradigm. (A): number of shocks received in the training 
day was altered in harmaline only group, which implies that fear learning, is altered by 
harmaline. (B): decreased step through latency (STL) indicates an impaired fear memory. 
Administration of WIN counteracted these impairments. (C): time in dark compartment was 
significantly increased by both the harmaline only and harmaline plus WIN groups. 
***p<0.001 as compared to control group; ## p<0.01as compared to harmaline group.  
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